At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
LCI699-matching placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension
In Brief
A Phase 2 clinical trial evaluating LCI699-matching placebo and LCI699 for Hypertension. Completed, enrolled 63 participants across 11 sites in 2 countries.
Detailed Summary
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesIceland, United States
CollaboratorsGreat Lakes Drug Development, Inc., Integrium
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartJan 2009
Primary CompletionAug 2009
TodayJul 2026
First PostedJan 6, 2009
Enrollment StartJan 14, 2009
Primary CompletionAug 12, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.5 years ago
Interventions
LCI699-matching placebodrug
LCI699-matching placebo oral capsules
LCI699drug
LCI699 oral capsules